Primer: RemeGen (9995 HK) - Aug 2026
RemeGen has successfully transitioned from a pre-revenue R&D company to a commercial-stage biopharmaceutical firm, achieving profitability...
111 Views
𝛼SK or SearchENTITY
RemeGen (9995 HK)
RemeGen (9995 HK)
311
Analysis
Health Care • China
RemeGen is a China-based biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on therapeutic antibody drugs, including antibody-drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies, for major diseases such as autoimmune disorders, oncology, and ophthalmology. Key products include Telitacicept (RC18) and Disitamab Vedotin (RC48). RemeGen was co-founded in 2008 and is headquartered in Yantai, Shandong Province, China.
morex